Abstract Library

#3850 [177Lu]-oxodotreotide in the treatment of gastroenteropancreatic neuroendocrine tumors – Patient profile in the REAL LU study (pRospective obsErvationAL study to assess the effectiveness and outcomes associated with LUtathera)

Introduction: Somatostatin (SST) receptor (SSTR) radioligand therapy is an option for highly SSTR-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The REAL LU study [NCT04727723] is evaluating the effectiveness of [177Lu]-oxodotreotide (LuO) in unresectable/metastatic, progressive, SSTR-expressing, Grade (G)1 or G2 GEP-NETs in clinical practice.

Conference:

Presenting Author:

Authors: Lastoria S, Tafuto S, Rodari M, Lania A, Sansovini M,

Keywords: REAL LU, GEP-NET, RLT, neuroendocrine tumor, radioligand therapy, [177Lu]-oxodotreotide,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,

#3373 Educational learning investigational observational study (ELIOS): A 10-year Italian network to standardize procedures and obtain multicentric clinical research studies

Introduction: Neuroendocrine neoplasms (NEN) are heterogeneous tumors with peculiar biology and rising incidence. Multidisciplinary approach in skilled centers is required to manage these patients. Accurate and complete data are indispensable for high quality epidemiological and clinical research.

Conference:

Presenting Author:

Authors: Modica R, Tafuto S, Riccardi F, Di Sarno A, Rodriquenz M,

Keywords: neuroendocrine, research, network,

#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study

Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,

Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,